Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.

Meanwhile, Lilly gets in on the next-gen KRAS action.

But the group’s attempt to join Janux at the high altar of masking technology falls flat.

Amid doubts about early data with FG-3246, the group is scathing about its rivals.

The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.

Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.

A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.

The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.